How to Microdose Hormones for Mood, Energy, and Body Composition

Part 2 of the supplement series. Why I use hormones differently

The same hormone that destroys bones can build them. Same hormone, different dose pattern. The drug your endocrinologist gives prostate cancer patients to shut down their testosterone is the exact molecule that can restart puberty in young men whose own pituitary axis cannot initiate it properly. One molecule. Opposite outcomes. The dose decides.

This is the cleanest principle in clinical endocrinology, and almost nobody applies the lesson to the hormones they take themselves. Your DHEA. Your pregnenolone. Your thyroid. Your progesterone. Your cortisol. Every one of them runs on this same logic. Small doses, delivered in the body’s natural rhythm, support the system. Large daily doses that flood the receptors without letting them recover suppress it. The pharmaceutical industry and the conventional medical model do not generally distinguish between these two modes. The discontinuation rate for standard HRT runs around 30 to 50 percent within the first year, with side effects and lack of felt benefit cited as the main reasons. The dosing is the problem more often than the molecule.

The smaller, smarter, more pro-metabolic way of using hormones to support a body back toward function. Microdosing. The word has become associated with psychedelics, but the actual clinical principle behind it is far older and applies to every steroid replacement protocol I have seen work.

The Dose-Response Reversal

The dose-response reversal is one of the most established principles in endocrinology. It explains why the conventional protocol for replacement therapy often makes people feel worse, why most thyroid prescriptions miss their target, and why so many women on a doctor’s protocol are still tired, still flat, still saying “this isn’t working.”

Crowley and colleagues at Massachusetts General Hospital demonstrated this in 1982 in the New England Journal of Medicine. Men with idiopathic hypogonadotropic hypogonadism, who could not undergo normal puberty because their pituitary axis was broken, received pulsatile low-dose GnRH delivered every 90 to 120 minutes by a portable infusion pump. Within one week their LH and FSH climbed to normal adult ranges. Within one month their testosterone rose from 77 nanograms per deciliter to 520. They had spontaneous erections and nocturnal emissions. Puberty restarted.

Give the same men continuous high-dose GnRH instead, and the opposite happens. The pituitary gets flooded. GnRH receptors downregulate. LH and FSH drop. Testosterone crashes. The entire HPG axis shuts down. That is precisely how GnRH agonists work as treatment for prostate cancer and precocious puberty. The drug suppresses gonadal function by overstimulating the receptor until the receptor stops responding.

Glucocorticoids do this. Pulsatile cortisol exposure preserves glucocorticoid receptor sensitivity by allowing the receptor pool to recover between pulses. Continuous high-dose synthetic glucocorticoid treatment, the way prednisone is typically prescribed for chronic inflammation, causes receptor downregulation. This is the molecular basis for the steroid resistance seen in patients on long-term prednisone. The receptors have been depleted by overexposure, and the drug stops working.

PTH does this most dramatically. Pulsatile low-dose parathyroid hormone is the active ingredient in teriparatide, an FDA-approved osteoporosis drug that builds bone. The exact same hormone in continuous high-dose form causes the bone destruction seen in hyperparathyroidism patients. One molecule. Two opposite outcomes. The dose pattern decides everything.

This is the textbook example every clinical endocrinology resident learns (or should learn) and then most of them forget by the time they are writing actual prescriptions.

Three Groups, Three Different Goals

Pre-menopausal women with suboptimal labs. Your cycle still runs. Your ovaries still produce estrogen and progesterone in the rhythm they always have. But your DUTCH test, your serum work, or just how you feel tells you the steroid cascade is running thin. Maybe your DHEA is low. Maybe your pregnenolone is depleted. Maybe your thyroid is technically in range and yet you feel none of the warmth, energy, and clear-headedness that proper thyroid function delivers. The labs come back fine. But the system is running suboptimally, and conventional medicine has nothing to offer until something breaks completely. The microdose approach exists precisely for this group, because the goal here is restoration. You are supporting your own production back toward fuller function, working alongside a cycle that is still running.

Perimenopausal women. Cycles becoming irregular, hormones crashing in waves, mood and sleep falling apart in clusters. The hormones you produce are erratic and dropping. The microdose approach still applies, with more flexibility built in, because what worked last month might not work this month. The body is moving through a transition, and the protocol has to move with it.

Postmenopausal women. Estrogen and progesterone production from the ovaries drops dramatically, and ovulation stops. Adrenal DHEA has also dropped significantly. The goal here shifts toward replacement, because you no longer have an endogenous cycle to titrate against. Doses can run higher than in the pre-menopausal group. Doses that push hormone levels above what a healthy younger body would produce are where the side effects start showing up. More is not better. Most women in this group are better served by physiological replacement than by the pharmacological doses that have been standard in conventional HRT for fifty years.

Note: While the broader principles in this article apply to both women and men, and the thyroid and "mother hormone" sections and their doses are universal, the rest of the dosing examples are female-centered.